Podcasts about alcohol use disorder

In this episode, we explore how naltrexone — the most widely used medication for alcohol use disorder in the US — works, how to dose it safely, and why liver disease may not be the barrier you think it is. Can a medication that doesn't target abstinence still be a game-changer for your patients? Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder Naltrexone for Alcohol Use Disorder: Dosing, Monitoring, and Liver Safety

What does it take to rebuild your life after decades of addiction, mental illness, and unimaginable loss?In this episode of the Sharing Without Shame podcast, host Donna Marston sits down with author Robert Rickelman to discuss his deeply personal journey through childhood trauma, severe anxiety, alcoholism, psychiatric hospitalization, and ultimately, lasting recovery.Robert shares how growing up with an alcoholic mother shaped his early life, why alcohol became his way of coping, and how addiction nearly cost him everything—including his health, relationships, and future. After years of detox programs, suicide attempts, hospitalizations, and searching for answers, Robert was diagnosed with serious mental health conditions that finally helped explain the struggles he had faced for most of his life.Together, Donna and Robert also explore:

In this episode, Dr Tsen Vei Lim talks to Dr Anastasia Demina, an addiction physician and researcher at the Dijon Bourgogne University Hospital and Université Bourgogne Europe, France. The interview covers Anastasia's randomised controlled triple-blind trial on the efficacy and safety of transcranial direct current stimulation in alcohol use disorder.The current available treatments for alcohol use disorder [01:11]Why transcranial direct current stimulation is needed [03:38]The process of transcranial direct current stimulation [04:51]The key findings of the study [07:31]How transcranial direct current stimulation works among current treatments for alcohol use disorder [12:21]The next steps for implementing transcranial direct current stimulation into clinical practice [16:04]About Tsen Vei Lim: Tsen Vei is an academic fellow supported by the Society for the Study of Addiction, currently based at the Department of Psychiatry at the University of Cambridge. His research integrates computational modelling, experimental psychology, and neuroimaging to understand the neuropsychological basis of addictive behaviours. He holds a PhD in Psychiatry from the University of Cambridge, UK, and a BSc in Psychology from the University of Bath, UK. About Anastasia Demina: Anastasia MD, PhD, is an addiction physician and researcher at the Dijon Bourgogne University Hospital and Université Bourgogne Europe. Her research focuses on optimising non-invasive brain stimulation to improve outcomes in individuals with substance use disorders, bridging neuroscience and clinical translation. She has led and contributed to clinical trials, systematic reviews and meta-analyses, and international collaborations in neuromodulation and addiction.Original article: Efficacy and safety of transcranial direct current stimulation in alcohol use disorder: A randomized controlled triple-blind trial https://doi.org/10.1111/add.70461The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information.Music provided by Jack Shakespeare. Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into the latest news shaping these dynamic sectors, exploring strategic corporate maneuvers, groundbreaking scientific advances, and pivotal regulatory changes. GlaxoSmithKline (GSK) is embarking on a comprehensive restructuring initiative aimed at achieving $2.5 billion in annual cost savings by 2029. This ambitious initiative underscores the company's commitment to strengthening its late-stage research and development capabilities. The strategy involves optimizing mature product lines, procurement processes, and supply chain efficiencies, reflecting broader industry trends where financial prudence is balanced with innovation. As part of this transformation, GSK plans to relocate its research headquarters near AstraZeneca's facilities, though specifics on employment impacts remain under wraps. This restructuring highlights the competitive nature of the pharmaceutical landscape and GSK's intent to maintain its edge through enhanced R&D initiatives. Meanwhile, Johnson & Johnson is nearing a resolution in its extensive talc litigation by proposing a $5.5 billion settlement to resolve approximately 76,000 lawsuits. These lawsuits allege that J&J's talc-based baby powder caused ovarian cancer. This potential settlement represents a significant step toward closing a protracted chapter of legal scrutiny for J&J, offering the company a chance to mitigate ongoing legal risks and refocus on core business operations. On the regulatory front, MannKind has secured FDA approval for its fast-acting edema autoinjector, reflecting an ongoing emphasis on addressing unmet medical needs with innovative delivery mechanisms. Conversely, Baxter has issued a recall for one lot of cefazolin in dextrose injection due to contamination concerns, underscoring the continuous challenges of ensuring product safety within complex manufacturing and supply chain environments. In terms of public health initiatives, Gilead Sciences is employing a novel approach to HIV prevention through its "Up to Date" campaign featuring comedians Nicole Byer and Devon Walker. This effort aims to destigmatize HIV discussions within the Black community by leveraging humor and relatability—a testament to evolving strategies in patient engagement and education. In drug development news, Atea Pharmaceuticals is making strides with its hepatitis C treatment candidate following positive Phase 3 trial results showing equivalence with Gilead's Epclusa. This positions Atea for further clinical evaluations and potential market entry with a simplified treatment regimen. Similarly, Hansoh Pharmaceutical's collaboration with GSK has yielded another Phase 3 success for their B7-H3-directed antibody-drug conjugate in China, highlighting the growing importance of targeted therapies in oncology. Emerging biotech hubs are reshaping the industry's landscape as cities beyond traditional centers like Boston and San Francisco gain prominence. This geographical diversification reflects global trends in biotech innovation and investment. In clinical advancements, Altimmune's GLP-1/glucagon receptor-targeting drug shows promise in reducing heavy drinking among individuals with alcohol use disorder (AUD). This finding opens new therapeutic avenues for AUD by leveraging mechanisms traditionally associated with weight loss medications. Concurrently, regulatory scrutiny remains high as Replimune faces setbacks with its melanoma data package deemed "not interpretable" by the FDA—an indication of the rigorous standards required for gaining regulatory approval. The geopolitical landscape also influences industry dynamics, particularly in China where intellectual property risks are heightened under new legislative acts. Companies must navigate these complexities strategically to protect innovations while capitalizing on market opportunities. Financially, Novo Holdings-backed Claris has secured $118 million in Series B funding to advance its corneal disease drug candidate—a substantial investment underscoring growing interest in ophthalmology therapeutics. Additionally, RA Capital has launched Oak Hill Bio onto Nasdaq via a special purpose acquisition company (SPAC), focusing on rare genetic diseases—a strategy showcasing continued momentum within biotech to leverage financial tools for niche therapeutic advancements. Overall, these developments reflect an industry characterized by rapid scientific progress and evolving regulatory landscapes. Companies are under pressure to optimize operations while ensuring robust clinical data to meet regulatory standards. As these sectors strive for innovation and patient care advancements amidst competitive global markets, balancing innovation with safety and efficacy remains paramount. As always, we'll continue to track these stories closely and bring you the latest insights right here on Pharma Daily.Support the show

Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: Multi-target trial emulation study BMJ Open This retrospective cohort study using target trial emulation evaluated the association between use of newer glucagon-like peptide-1 receptor agonists (GLP-1 RAs; semaglutide, tirzepatide) and alcohol-related hospitalizations among adults with alcohol use disorder (AUD) and type 2 diabetes (T2D) or obesity. The authors found that among adults with AUD and T2D or obesity, initiation of newer GLP-1 RAs was associated with a lower observed risk of alcohol-related hospitalization.    Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

I want to tell you about my friend Larry. Larry is pretty well known in the podcast world as a content creator, a consultant, and a subject matter expert for journalists. I've seen lots of times where he's appeared on local and national TV shows, talking about podcasting as well as AI – he's been on the forefront of how to use AI for personal and business productivity. And he's been a sought-after keynote speaker at lots of organizations where he talks about these things. A few years ago, Larry and I were in Los Angeles during a podcasting conference. One evening during that week there was a big podcast awards show, and there was an after party. I don't usually go to those things, but for some reason I was there. It was a private party but lots of people were there and it was on a rooftop bar, I don't even remember the name of it. Of course the music was loud, and you would never guess who the DJ was – Paris Hilton. It was pretty crazy. And of course I would see Larry every year in January in Orlando, at the conference called Podfest. But this past January I didn't see Larry. I didn't know why he wasn't there, and honestly I didn't think about it a lot. It's always a busy week and there are a couple thousand people there. But what I didn't know was that Larry was in rehab at that time. He was trying to overcome Alcohol Use Disorder. Maybe better known as alcoholism. Larry's life is very different now. His addiction to alcohol means he no longer has his business, his house, his cars, his wife – all gone. He's working on his comeback now, and he told me the whole story which you're about to hear. I also need to include a content warning for discussion of suicide. What Larry didn't know at the time was - when he missed that Orlando conference because of being in rehab – he had not yet reached his rock bottom. If you'd like to contact Larry or follow his journey: Instagram: @thelarryroberts Facebook: @thelarryroberts website: https://LarryRoberts.com Full show notes and pictures for this episode are here: https://WhatWasThatLike.com/263 Graphics for this episode by Bob Bretz. Transcription was done by James Lai. Want to discuss this episode and other things with thousands of other WWTL listeners? Join our podcast Facebook group at WhatWasThatLike.com/facebook (many of the podcast guests are there as well) Get every episode ad-free, AND get all the Raw Audio exclusive episodes to binge, by joining the other listeners at What Was That Like PLUS. Try What Was That Like PLUS free: iPhone: at the top of the What Was That Like podcast feed, click on “Try free” Android: on your phone, go to WhatWasThatLike.com/PLUS and click to try it free on any app Sponsor deals: Quince - Go to Quince.com/whatwas for free shipping on your order and 365-day returns! Boll & Branch - get 15% off your first order AND free shipping: BollandBranch.com/WHATWAS Nutrafol - Get $10 off your first month's subscription, and free shipping: use promo code WHATWAS at Nutrafol.com Try Mint Mobile for 3 months, for just 15 bucks a month - MintMobile.com/WHAT Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us Fan MailIn this next installment of Translational Conversations, we talk with Dr. Danny Winder, a mouse researcher, and Dr. Jenni Blackford, a human researcher, about how their years of collaborations across species have revealed important insights into the different ways Alcohol Use Disorder (AUD) can present in individuals. We hear about how their translational research process has led to significant scientific discoveries regarding the relevant brain circuits and sex differences that influence AUD. In this discussion, Dr. Winder and Dr. Blackford share the story behind the start of their collaboration, ways in which their work has inspired one another to explore new directions, and how their continued work together has culminated in the development of a multidisciplinary, cross-species center grant that brings together experts from several institutions around the country.We appreciate Dr. Danny Winder, the Neurobiology Department Chair and Worcester Foundation of Biomedical Research Professor at UMass Chan Medical School and Dr. Jenni Blackford, the Hattie B. Munroe Professor and Associate Dean of Research at the Munroe-Meye Institute of the University of Nebraska Medical Center, for joining us in this discussion on the translational research process, and for sharing their research and important perspectives.Episode Note: This episode was filmed in April, prior to a symposium that Drs. Blackford and Winder presented at a conference in May. In the episode, this symposium is referenced in the future tense as an example of ways that researchers across species can practice the translational process and improve collaborative efforts. Translational Conversations is made possible through support from Biomedical Research Awareness Day, a program of Americans for Medical Progress, and the American College of NeuropsychopharmacologyFollow Dr. Jenni Blackford on Bluesky@jenniblackford.bsky.social@bnsteam.bsky.social@unmc.bsky.socialFollow Dr. Danny Winder on Bluesky and LinkedIn@Dgordonwinder.bsky.socialhttps://www.linkedin.com/in/danny-winder-609123187/Support the showFollow Lab Rat Chat on X! Facebook! Instagram!https://twitter.com/thelabratchat https://www.facebook.com/labratchat https://www.instagram.com/thelabratchat All Lab Rat Chat episodes are edited by Audionauts: https://audionauts.pro/ 

Naltrexone is often a first-line medication for AUD. It works as an opioid receptor antagonist, reducing the rewarding effects of alcohol and decreasing cravings. Patients frequently report that alcohol becomes less pleasurable while taking the medication. Oral naltrexone is typically dosed at 50 mg daily, while a long-acting injectable formulation is also available. Avoid use in patients taking opioids and use caution in significant liver dysfunction. Acamprosate helps maintain abstinence by modulating glutamate and GABA neurotransmission. Chronic alcohol use disrupts the balance between excitatory and inhibitory pathways in the brain, and acamprosate helps restore equilibrium. It is primarily eliminated renally, making it a useful option in patients with liver disease. The most common adverse effect is diarrhea. Disulfiram works through a completely different mechanism. It inhibits aldehyde dehydrogenase, causing acetaldehyde accumulation when alcohol is consumed. This can lead to flushing, nausea, vomiting, headache, and hypotension. Because of this aversive reaction, patient motivation and adherence are critical for success. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE! Support The Podcast and Check Out These Amazing Resources! NAPLEX Study Materials BCPS Study Materials BCACP Study Materials BCGP Study Materials BCMTMS Study Materials Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated) Guide to Drug Food Interactions (Amazon Best Seller) Pharmacy Technician Study Guide by Meded101

You have the career. The family. The responsibilities.So why does that glass of wine feel harder to say no to?In this episode of Sober & Lit, we're exploring the hidden connection between alcohol, anxiety, and women.You'll discover:Why anxiety can quietly increase drinkingHow alcohol becomes a coping habitThe surprising science behind "telescoping"Why this isn't a willpower problemSimple tools to calm anxiety without alcoholIf you've ever thought:"Why am I drinking more than I want to?""Why does alcohol help... and then make everything worse?""Why can't I seem to break the cycle?"This episode offers hope, science, and practical strategies to help you understand what's really happening beneath the habit and how to find relief without relying on alcohol.We Love Hearing From YouDon't forget to follow and subscribe and leave a review! It helps to get the word out that living sober is lit! Listeners have said that our podcast has helped them get alcohol free! Join our private community! Connect with the Podcast Hosts:Susan Larkin Coaching https://www.susanlarkincoaching.com Ruby Williams at Freedom Renegade Coaching https://www.freedomrenegadecoaching.com/Follow Susan: @drinklesswithsusanFollow Ruby: @rubywilliamscoachingIt is strongly recommended that you seek professional advice regarding your health before attempting to take a break from alcohol. The creators, hosts, and producers of the The Feel Lit Alcohol Free podcast are not healthcare practitioners and therefore do not give medical, or psychological advice nor do they intend for the podcast, any resource or communication on behalf of the podcast or otherwise to be a substitute for such.

Alcohol use disorder affects millions of Americans, but treatment options remain limited, and relapse is common. A UT Health San Antonio researcher is studying two unconventional approaches that he hopes could one day be combined into a single, more effective treatment.

Why do so many adults with ADHD struggle with alcohol, even when they know it's not helping them? In this episode, Lynne Edris talks with Colleen Freeland about the powerful connection between ADHD, dopamine, nervous system regulation, and alcohol use. They explore: • Why ADHD brains often seek relief through alcohol and other coping behaviors • The difference between drinking for pleasure and drinking for relief • How dopamine and urgency drive unhealthy patterns • Why shame keeps us stuck • How to build healthier responses to stress and overwhelm • The mindset shift that makes lasting change possible Whether alcohol is your challenge—or whether your coping mechanism looks more like procrastination, scrolling, shopping, or overworking—this conversation will help you better understand your brain and create change with more compassion and less self-judgment. Colleen Freeland is an Intuitive Drinking Coach and host of the globally top-ranked It's Not About the Alcohol podcast. Colleen founded Emotional Sobriety Coaching© for high achieving professional women who want to reduce alcohol consumption by 80 percent. She combines holistic and evidence-based strategies in Neurophysiology, Cognitive Reframing, and Spirituality to reprogram the mind and body - so you actually prefer drinking in moderation. Colleen secretly struggled with Alcohol Use Disorder for over 20 years before discovering that the solution to overdrinking is to get happy, not sober. She is an Addiction and Recovery-Certified Master Life Coach with an MSc in Health Coaching, a BS in Biology and Chemistry Education, and is certified as a Women's Functional and Integrative Health Professional. Learn more about Colleen at https://www.emotionalsobrietycoaching.com/ Podcast Co-Host Lynne Edris s a Productivity & ADHD Coach who helps distracted professionals from all over the world learn to accomplish what they intend and take control of their days with ease so that they can perform at the level of their abilities and have more time, more energy and more bandwidth for what matters most to them. Lynne is a woman, wife, and mom with ADHD herself, so she understands the struggles and challenges of living with ADHD. She has gone from living in the constant state of chaos, overwhelm, and under-performance that adults with ADHD know far too well, to living a life of more success and fulfillment than she once dreamed possible. Her passion is to help others fulfill their own potential and start "firing on all cylinders" in all areas of your life. You can learn more about Lynne at www.CoachingADDvantages.com, and visit www.ProductivityBreakthroughQuiz.com to take her complimentary self-assessment! RESOURCES & LINKS Take Lynne's Productivity Breakthrough Quiz: https://www.productivitybreakthroughquiz.com Learn more about Lynne Edris: https://www.coachingadvantages.com Learn more about Colleen Freeland at https://www.emotionalsobrietycoaching.com/ Join the ADHD Support Talk Facebook Community: https://www.facebook.com/groups/adhdsupporttalk We'd love to hear from you! ADHD Support Talk Radio is an award winning Podcast for Adults with ADD / ADHD. Co-hosts Tara McGillicuddy and Lynne Edris are joined by Adult ADHD experts and they cover important topics related to Adult ADD / ADHD. Podcast guests include Dr. Edward Hallowell, Dr. Stephanie Sarkis, Dr. Ari Tuckman, Laurie Dupar, Terry Matlen and many more. Tara McGillicuddy is the Producer, Owner and Co-host of the ADHD Support Talk Radio Podcast. You may contact Tara with general questions or feedback about the podcast, Lynne Edris is the Co-host of the ADHD Support Talk Radio Podcast. You may contact Lynne with feedback about her episodes or if you are interested in having her interview you as a guest. https://adhdsupporttalk.com/about-podcast/ We may be an affiliate for products we mention or recommend. If you purchase those items through our links, we may earn a commission.

CM Bob Kettle says Mayor Wilson is violating city law over CCTV cameras ahead of World Cup //Seattle’s Pioneer Square gets a revamp ahead of World Cup 2026 // UW studying whether GLP-1 drugs, like Ozempic, can treat alcohol-use disorder // The science around GLP-1 drugs and cancer is suddenly getting a lot more interesting // LETTERS